Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Dow
Cantor Fitzgerald
Medtronic
Argus Health
Queensland Health
Fuji
Farmers Insurance
Chubb

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206619

« Back to Dashboard

NDA 206619 describes VIEKIRA PAK (COPACKAGED), which is a drug marketed by Abbvie Inc and is included in one NDA. It is available from one supplier. There are eighteen patents protecting this drug. Additional details are available on the VIEKIRA PAK (COPACKAGED) profile page.

The generic ingredient in VIEKIRA PAK (COPACKAGED) is dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir. One supplier is listed for this compound. Additional details are available on the dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir profile page.
Summary for 206619
Tradename:VIEKIRA PAK (COPACKAGED)
Applicant:Abbvie Inc
Ingredient:dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
Patents:18
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 206619
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619 NDA AbbVie Inc. 0074-3093 N 0074-3093-01
VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619 NDA AbbVie Inc. 0074-3093 N 0074-3093-28

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, TABLET;ORALStrengthEQ 250MG BASE,N/A,N/A,N/A; N/A,12.5MG,75MG,50MG
Approval Date:Dec 19, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Apr 22, 2019
Regulatory Exclusivity Use:DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1A INFECTION WITH COMPENSATED (CHILD-PUGH A) CIRRHOSIS AND GENOTYPE 1B WITH OR WITHOUT COMPENSATED (CHILD-PUGH A) CIRRHOSIS
Regulatory Exclusivity Expiration:Dec 19, 2019
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ Try a Free TrialPatent Expiration:Jul 19, 2019Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 206619

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Argus Health
Chinese Patent Office
McKinsey
Farmers Insurance
Cipla
Medtronic
Covington
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.